The MAP target after acute spinal cord injury was never a trial result. In 2024 it was formally lowered, and the reason was not new evidence of benefit but the first honest accounting of what the vasopressors cost.
For three decades the teaching was a floor — keep the MAP above 85 to 90 for seven days — and that number came from a small uncontrolled series, not a trial. The 2024 AO Spine and PRAXIS guideline replaced the floor with a band, at least 75 to 80 as a lower limit and not actively pushed beyond 90 to 95, for three to seven days. Nothing new was learned about benefit. What changed is that the harms of the vasopressors used to reach the old number were finally counted on the same page.
Spinal cord perfusion pressure is mean arterial pressure minus the pressure in the thecal sac. That subtraction is the whole of the physiology, and it explains why a MAP target is a proxy rather than the quantity anyone actually wants to control.
In an uninjured cord, autoregulation holds flow roughly constant across a wide range of perfusion pressures. Injury abolishes it locally. Within the injured segment and for some distance around it, flow becomes pressure-passive — whatever perfusion pressure you deliver is what the tissue gets. That is the argument for supporting the systemic number, and it is sound as far as it goes.
The complication is that the other term in the subtraction does not sit still. The cord swells over the first several days inside a dural sac that cannot expand, so intrathecal pressure rises. A MAP held perfectly steady at 85 therefore corresponds to a falling perfusion pressure across exactly the window in which the target is being maintained. Direct measurement of intrathecal pressure is possible and has been studied, but it is not routine care, so in practice the term nobody measures is the one that moves.
Set against that is a harm curve that is much better characterised. Reaching a high MAP in a patient who is vasoplegic and bradycardic means sustained vasopressor infusion, and the complications — arrhythmia, myocardial ischaemia, and the volume load that accompanies the attempt — have been counted repeatedly in this population. They rise steeply at the upper end of the range.
So the honest statement of the problem is two curves whose crossing point has never been located. A guideline that responds by giving a band rather than a number is not being vague. It is declining to invent a precision that the evidence cannot support.
No randomized trial addresses this.
The physiology is not in doubt. Spinal cord perfusion pressure is mean arterial pressure minus the pressure in the thecal sac, autoregulation is impaired in the injured segment, and perfusion there becomes pressure-passive. Every step of that is established.
What has never existed is a randomized comparison of one MAP target against another. The original figure entered practice through a single-centre uncontrolled series in the 1990s in which patients managed with aggressive haemodynamic support appeared to do better than historical controls. It was then repeated in guidelines, and repetition was mistaken for accumulation. The 2024 systematic review that underpins the current guideline found the evidence base still consists of small cohorts and registry analyses with serious risk of bias and no comparative trial of targets.
The 2024 guideline therefore does two things worth noticing. It lowers the lower limit, and it adds an upper limit — which the old teaching never had, because a floor with no ceiling quietly authorises any dose of vasopressor needed to clear it.
Strength, in the guideline's own words Both the MAP-target and the duration recommendations are graded a "weak" recommendation on "very low" quality of evidence.
The characteristic error here is not choosing the wrong target. It is treating any specific number as though a trial produced it, and then defending it with the confidence that only trials earn.
You will see this concretely when the MAP reads 78 in a patient with a cervical injury and someone escalates norepinephrine to reach 85. That action treats 85 as a threshold with a mechanism behind it. It is not one. It is the midpoint of a range in a guideline that grades its own confidence as very low, and the escalation has a real and countable cost on the other side of the ledger.
The tell that you have slipped into this error is the language. When the conversation is about whether the patient is perfusing — urine output, lactate, the exam where an exam is still possible — you are reasoning about a patient. When it is about whether the number is above the line, you are reasoning about the number.
Full text · Preston goes through LibKey to whatever Preston holds — the PDF where there is one — and works on a phone. The doi link always reaches the publisher's record, whether or not we hold a subscription. If you are reading on a computer, LibKey Nomad adds the same one-click PDF button to PubMed and publisher pages everywhere else; it is a desktop browser extension, so it does nothing on a phone or tablet.
A 24-year-old with a C6 ASIA B injury is 18 hours out from fixation. MAP reads 78 mm Hg on a low-dose norepinephrine infusion. Urine output is adequate and lactate is normal. The night resident proposes increasing the norepinephrine to reach a MAP of 90. Which response best reflects the 2024 guideline?
Why can a MAP that has not changed still correspond to a falling spinal cord perfusion pressure in the days after an acute cord injury?
The 2024 hemodynamic recommendations are graded a weak recommendation on very low quality evidence. What is the correct practical reading of that grading?
This is the dose given for both laryngoscopy and pin placement. Remifentanil 0.5 to 1 µg/kg and propofol 0.5 to 1 mg/kg are the alternatives for the pins, and local infiltration of the pin sites adds to all of them.
These are ordered by how fast they work and by how reversible they are. Obstructed venous outflow and an unnoticed rise in CO₂ are the two fastest fixes and the two most often missed. Volatile agents cause cerebral vasodilation, and the standing advice is to replace them with an intravenous technique whenever measures to control brain bulk are unsuccessful. Osmotic diuretics are effective but slow, so they are started early and relied on late.